Vermillion, Inc. to Host Teleconference and Webcast on Thursday, August 30, 2007 at 9:00 a.m. Eastern

FREMONT, Calif., Aug. 29 Vermillion, Inc.(Nasdaq: VRML), will host a teleconference and webcast on Thursday, August 30at 9:00 a.m. Eastern Time to discuss its name change and provide an update onbusiness developments. To access the live conference call via phone, dial(877) 325-7371 from the United Statesand Canadaor (706) 634-0768internationally. The conference ID is 21347583. Please dial-in approximatelyten minutes prior to the start of the call. Additionally, you may access thelive and subsequently archived webcast of the conference call from theInvestor Relations section of the Company's website athttp://www.vermillion.com. Please connect to the web site at least 15 minutesprior to the call to allow for any software download that may be necessary.

(Audio: http://www.videonewswire.com/event.asp?id=42105)

A telephone replay will be available beginning approximately two hoursafter the call through Sept 13, 2007 and may be accessed by dialing(800) 633-8284 from the United States and Canada or (+1 402) 977-9140internationally. The replay passcode is 21347583. An archived replay of thewebcast will be available until the next quarterly call.

About Vermillion, Inc.

Vermillion, Inc. is dedicated to the discovery, development andcommercialization of novel high-value diagnostic tests that help physiciansdiagnose, treat and improve outcomes for patients. Vermillion, along with itsprestigious scientific collaborators, has ongoing diagnostic programs inoncology/hematology, cardiology and women's health with an initial focus inovarian cancer. Based in Fremont, California, more information aboutVermillion can be found on the Web at http://www.vermillion.com.

SOURCE Vermillion, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...